



Forward Looking Statements

The statements made during today's presentation or in response to questions, may contain forward-looking information as defined under applicable Canadian securities legislation, herein called "forward-looking statements". Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company's actual results to differ materially from those in the forward-looking statements.

Such risks and uncertainties include, but are not limited to, the availability of funds and resources to pursue R&D activities, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in its specific industry, uncertainties related to the regulatory process and general changes in economic conditions.

Investors should consult the Company's ongoing filings with the Canadian securities authorities for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. Except as required by law, the Company undertakes no obligation to update these forward-looking statements whether as a result of new information or future events or otherwise.

Luminor Medical' s Mission

Our Mission is to improve the lives of people with diabetes and pre-diabetes by successfully identifying, developing, maximizing, and commercializing innovative MEDICAL TECHNOLOGIES.

Be a diversified Diabetes Medical Technologies Co.

Achieve revenues of > \$250 million and profits >50%

Phase 1. SCOUT DS

Scout DS®: Non-Invasive
Proprietary medical device
approved for distribution in
>40 countries

Phase 2. Late Stage Medical Device Acquisition in Large Mature Market

1. Strips for Glucometer
2. Accessories
3. Medical Food
4. Ulcer gel

Lean and outsourced organisation focused on acquiring and commercialising
differentiated solutions for people with Diabetes and Pre-Diabetes

Managing Directors



Christian Sauvageau, CEO

30 years of management and leadership experience in both pharmaceutical and medical device businesses - Canada, US and International.

Lead business unit up to \$600M annual revenue and teams of 5-500

Expertise in diabetes, product launch, hospitals, and health management



Chris Carmichael, CFO

CEO Bradstone Capital Corp. a Canadian based merchant banking organization.

20 years providing financial reporting services for publicly traded companies

Certified Public Accountant and Certified General Accountant. B.A. in

Administrative and Commercial Studies, Financial and Economic Stream in 1996

and Business Degree from the University of Western Ontario

See complete bio p. 24

Scout DS® – Lead Technology

- Non-invasive and user-friendly
 - No needles or blood draw
 - No fasting
 - No solvent or solution
 - Portable – lite weight
- 90 second test with immediate results
- Approved for sales in 33 countries
- Patent protected
- \$42.5 million invested in R&D [2006-2012]
- High margin




Scout DS[®], a ground-breaking diabetes-screening device that uses visible light to fluoresce, detect and measure biomarkers present in the skin

Uses visible light to fluoresce, detect and measure biomarkers present in the skin associated with pre-diabetes and type 2 diabetes

Detects abnormal glucose tolerance just as well as Fasting Plasma Glucose and HbA1c testing

Tested in > 20 Studies. Research studies have tested >15,000 Subjects and > 5,000 commercially

CE Mark and Health Canada certification



Consumer Options Diabetes Screening

Invasive (Blood)

Fasting Plasma Glucose (FPG)
Hemoglobin A1C (HBA1c)
Oral Glucose Tolerance Test (OGTT)
Finger Stick Blood Glucose



Non-Invasive (Light)

Scout DS®



Scout DS® Eliminates Barriers to Screening

Test	Noninvasive	Non-Fasting	Consistent Results	High Sensitivity	Immediate Results	Easy to Use	Cost-Effective
SCOUT DS®	✓	✓	✓	✓	✓	✓	✓
Fasting Plasma Glucose			✓				
Oral Glucose Tolerance Test				✓			
Hemoglobin A1c		✓	✓	✓			
Finger Stick Blood Glucose					✓	✓	

SCOUT is the only diabetes screening device that is non-invasive, does not require fasting, offers high sensitivity and delivers immediate results at the point of care

Strong Intellectual Property


Patent Coverage

- Diabetes screening, CAD screening, disease detection and monitoring using fluorescence, near infrared and/or raman spectroscopy
- Patents issued/pending in Europe, Canada, India, Japan, China and Korea
- Patents issued in U.S.

Trade Secrets

- Proprietary, encrypted algorithms
- Instrument standardization methods and materials

422 Million adults living with Type 2 Diabetes in the World and more than 1.1 Billion with Pre-Diabetes




Developing World,

272 million adults with diabetes, >50% are undiagnosed

Blood glucose measurement tests are available in less than 50% of the developing world


FIGURE 12. PERCENTAGE COUNTRIES REPORTING OTHER TECHNOLOGIES AS GENERALLY AVAILABLE IN PUBLICLY-FUNDED PRIMARY HEALTH-CARE FACILITIES




National population-based survey with **glucose measurement** are the **first step** to control the **diabetes epidemic**

Impact of Diabetes

- Vision loss, heart attack, kidney failure, stroke, leg amputation, nerve damage
- Catastrophic medical expenditures significantly higher in people with diabetes affecting nations and families
- Direct annual cost of diabetes globally > US\$ 827 billion.
- Losses in GDP worldwide estimated to be US\$ 1.7 trillion from 2010 to 2030



SCOUT DS® - Business Plan





CHINA – Licensing Opportunity

The prevalence of diabetes in Chinese adults has increased from less than 1 per cent in 1980 to 9.4 per cent in 2014

Researchers estimate that >600 million people in CHINA live with Pre-Diabetes or Diabetes and the majority are unaware of their situation

We estimate that a revenue sharing model with China Hospital could generate 5,000 tests per day per Class 3A hospital and would support the deployment of 20 SCOUT DS® per hospital. There are about 1600 Class 3A hospital in China.

Market potential > 100,000 SCOUT DS®

In discussion with interested Licensing parties



INDIA – Distribution

Diabetes is gaining the status of an epidemic in India with more than 62 million diabetic individuals currently diagnosed and at least another 120 million with pre-diabetes.

HbA1c test is not easily available to a large section of Indian population

Market potential > 20,000 SCOUT DS®

In discussion with interested distributor



US – FDA Opportunity

The majority of 86 million Americans live with Pre-Diabetes and are unaware of their situation

- The U.S. Centers for Disease Control and Prevention (CDC) estimates that 1 of every 3 U.S. adults had pre-diabetes in 2010.*

The US Centers for Medicare and Medicaid Services (CMS) has announced that, as of January 1, 2018, it will be expanding the Diabetes Prevention Program (DPP) to provide coverage for all eligible at-risk beneficiaries with prediabetes who are aged 65 years or older. Any healthcare provider certified by the Centers for Disease Control and Prevention will be eligible to administer the diabetes prevention program.

Seeking Licensing party, JV Partner, and or US Lead Investor

** Source: US Centers for Disease Control and Prevention*



US Non-Dilutive Funding

**\$50B USD
annually**

Non-Dilutive
Market



- **HHS- NIH**
 - 27 institutes and centers including NCI, **NIDDK**, NINDS, NIAID, NIMH, NIBIB, NIDA, NHLBI, NEI, NIA, etc.
- **Other HHS Organizations**
 - BARDA, FDA, **CDC**, NSF
- **Department of Defense **[DOD]****
 - US Army, DARPA, DTRA, CDMRP, etc.
- **Private Foundations**
 - **Gates**, MJ Fox, ADDF, and many more

Luminor hired FreeMind (est. in 1999), the largest consulting group working with academics and industry to maximize the funding from NIH Institutes, Department of Defense, NSF, FDA, BARDA, etc., as well as private foundations.

Goal: Support SCOUT DS® development and introduction in USA

Financial Overview

BASE CASE FORECAST				
	2017	2018	2019	2020
SCOUT INTL	\$ 3 500 000	\$ 7 800 000	\$ 27 690 000	\$ 52 500 000
SCOUT US		\$ 4 800 000	\$ 22 500 000	\$ 42 500 000
TOTAL Revenues	\$ 3 500 000	\$ 12 600 000	\$ 50 190 000	\$ 95 000 000
COG Scout DS	\$ 875 000	\$ 3 150 000	\$ 12 547 500	\$ 23 750 000
Gross Margin	75%	76%	77%	78%
Distribution	\$ 700 000	\$ 2 898 000	\$ 12 045 600	\$ 22 800 000
R&D	\$ 700 000	\$ 1 000 000	\$ 1 200 000	\$ 1 200 000
Reg / IP	\$ 300 000	\$ 300 000	\$ 300 000	\$ 300 000
A&P	\$ 75 000	\$ 750 000	\$ 1 300 000	\$ 1 700 000
G&A	\$ 500 000	\$ 1 450 000	\$ 2 000 000	\$ 2 500 000
Total Expenses	\$ 3 150 000	\$ 9 548 000	\$ 29 393 100	\$ 52 250 000
EBITDA	\$ 350 000	\$ 3 052 000	\$ 20 796 900	\$ 42 750 000

LMT has gone through a complete restructure in the share capital, debt clean-up and new management. Now focused on priorities – Scout DS™: Manufacturing, FDA, China and India



Capital Request

- Luminor intend to raise C\$3 million through private placement in April-May 2017 to execute the Scout DS and Luminor strategy

Uses

Uses

(in \$ millions)

C\$

Transaction Costs	\$	0,3
Scout DS Manufacturing	\$	1,0
CHINA: FDA and IP	\$	0,8
Business Development	\$	0,5
Working Capital	\$	0,4
Total Uses	\$	3,0

Corporate Overview

Business Overview

Exchange Ticker	TSX-V : LMT
Focus	Non-Invasive Diagnostics, Chronic disease prevention and intervention in Diabetes
Headquarters	Montreal, Quebec, Canada
Management	Dedicated Experienced Management (CEO, CFO)
Investment R&D / Patent	\$ 42.5 million
Product Pipeline	Diabetes, Cardiovascular non-invasive tests, acquisition

Financial Overview

Basic Shares Outstanding	9.4 million
Insider Holding	20%
Market Capitalization	\$ 5.1 million
Share Price [52 weeks]	\$0.14-0.75

Management Team

Christian Sauvageau President & CEO

Mr. Sauvageau has 30 years of experience in both the pharmaceutical and medical device fields.

He has held senior sales, marketing, and business development positions with both national and international experience.

>20 years at Merck Canada Ltd most recently as Vice President of customer innovation where he launched innovative products and practices. He led business units to \$600 million in annual revenue

Mr. Sauvageau graduated with a B.Sc.(Biochemistry) from University Laval in Quebec, Canada and was an Officer of the Canadian Armed Forces. Christian combines a high degree of ethics and integrity to a passion for patient health and business results.

Chris Carmichael CFO

CEO Bradstone Capital Corp. a Canadian based merchant banking organization

20 years providing financial reporting services for publicly traded companies on TSX, TSX Venture Exchange, CNSX and pre-public companies.

Certified Accountant, graduated from Western University with B.A. (Business).

As a person with type 1 diabetes, Chris understands the challenges our target customer live on a daily basis



Board of Director

Executive	Experience
Harry Bloomfield Chairman	<ul style="list-style-type: none"> • Mr. Bloomfield is a lawyer, business manager and philanthropist. Mr. Bloomfield specializes in Canadian Federal and Provincial Corporate Law, International Finance, Securities Matters; International Taxation law. From 1980 to 1987, he was Minister of Financial Institutions of Quebec as Member of the Commission, Commission Des Valeurs Mobilières Du Quebec (Quebec Securities Commission). He has been an Independent Director of Miraculins Inc. since May 31, 2011. Mr. Bloomfield received Law Degree, LL.B. in June 1968 from the University of Montreal, and graduated from Harvard School of Business Administration, and holds an M.B.A. Degree.
Ashwath Mehra Director	<ul style="list-style-type: none"> • Mr. Mehra, B.Sc. (Econ), serves as Chief Executive Officer of the Astor Group, an investment and advisory group of businesses. Mr. Mehra has worked in the minerals industry for 22 years. He has extensive experience in international business , restructuring, risk management, board leadership, debt and equity financings, and M&A. He has been Independent Director of Miraculins Inc. since February 9, 2016. Mr. Mehra holds a BSc Degree in Economics and Philosophy from the London School of Economics and Political Science.
Daniel Cloutier Director	<ul style="list-style-type: none"> • Daniel Cloutier is the CEO of LOK Corporation, based in Hong Kong which specializes in services to Medical Device manufacturers. LOK Corporation’s core business is oriented on manufacturer agent from strategic business development, in country representation, regulatory, establishing channel of distribution to territory management. They reach a Network of more than 15 000 distributors worldwide. Daniel has 20 years of experience as international Sales Director and Global Vice president in distribution of leading public medical device Companies. He launched a number of new product internationally.
Christian Sauvageau Director	<ul style="list-style-type: none"> • President & CEO of Luminor Medical Technologies

Scout DS®

Selected Clinical Validations

- [1] Olson BP, Matter NI, Ediger MN, Hull EL, Maynard JD. Noninvasive Skin Fluorescence Spectroscopy is Comparable to HbA1c and Fasting Plasma Glucose for Detection of Abnormal Glucose Tolerance. *Journal of Diabetes Science and Technology*, 7:990-1000, 2013.
- [2] Tentolouris N, Lathouris P, Lontou S, Tzemos K, Maynard J. Screening for HbA1c-Dened Prediabetes and Diabetes in an At-Risk Greek Population: Performance Comparison of Random Capillary Glucose, the ADA Diabetes Risk Test and Skin Fluorescence Spectroscopy. *Diabetes Research and Clinical Practice*, 100:39-45, 2013.
- [3] Viswanathan Mohan, C.S. Shanthy Rani, Bhaskaran S. Regin, Muthuswamy Balasubramanyam, Ranjit M. Anjana, Nathaniel I. Matter, Subramani Poongothai, Mohan Deepa, Rajendra Pradeepa. Noninvasive Type 2 Diabetes Screening: Clinical Evaluation of SCOUT DS in an Asian Indian Cohort. *Diabetes Technology and Therapeutics*, 15:39-45, 2013.
- [4] Orchard T, Lyons TJ, Cleary PA, Braett BH, Maynard J, Cowie C, Gubitosi-Klug RA, Way J, Anderson K, Barnie A, Villavicencio S, and the DCCT/EDIC Research Group. The association of Skin Intrinsic Fluorescence with Type 1 Diabetes Complications in the DCCT/EDIC Study. *Diabetes Care*, published online, June 28, 2013.
- [5] Cleary PA, Braett BH, Orchard T, Lyons TJ, Maynard J, Cowie C, Gubitosi-Klug RA, Anderson K, Barnie A, Villavicencio S, and the DCCT/EDIC Research Group. Clinical and Technical Factors Associated with Skin Intrinsic Fluorescence in Subjects with Type 1 Diabetes from the DCCT/EDIC Study. *Diabetes Technology and Therapeutics*, 15:466-474, 2013.
- [6] Conway B, Aroda V, Maynard J, Matter N, Fernandez S, Ratner R, Orchard T. Skin Intrinsic Fluorescence is Associated with Coronary Artery Disease in Individuals with Long Duration of Type 1 Diabetes. *Diabetes Care*, 35:2332-2336, 2012.
- [7] Conway B, Aroda V, Maynard J, Matter N, Fernandez S, Ratner R, Orchard T. Skin Intrinsic Fluorescence Correlates With Autonomic and Distal Symmetrical Polyneuropathy in Individuals With Type 1 Diabetes. *Diabetes Care*, 34:1000-1005, 2011.
- [8] Shah S, Baez E, Felipe D, Maynard J, Hemepe J, Chalew S. Advanced glycation end products in children with diabetes. *Journal of Pediatrics*, published online: August 5, 2013.
- [9] Aroda V, Conway B, Fernandez S, Matter N, Maynard J, Orchard T, Ratner R. Cross-Sectional Evaluation of Noninvasively Detected Skin Intrinsic Fluorescence and Mean Hemoglobin A1c in Type 1 Diabetes. *Diabetes Technology and Therapeutics*, 15:117-123, 2013.
- [10] Felipe D, Hemepe J, Liu S, Matter N, Maynard J, Linares C, Chalew S. Skin Intrinsic Fluorescence is Associated With Hemoglobin A1c and Hemoglobin Glycation Index but Not Mean Blood Glucose in Children With Type 1 Diabetes. *Diabetes Care*, 34:1816-1820, 2011.
- [11] Conway B, Edmundowicz D, Matter N, Maynard J, Orchard T. Skin Fluorescence Correlates Strongly with Coronary Artery Calcification Severity in Type 1 Diabetes. *Diabetes Technology and Therapeutics*. 12:339-345, 2010.
- [12] Ediger M, Olson B, Maynard J. Noninvasive Optical Screening for Diabetes. *Journal of Diabetes Science and Technology*, 3: 776-780, 2009.
- [13] Maynard J, Rohrscheib M, Way J, Nguyen C, Ediger M. Noninvasive type 2 diabetes screening: superior sensitivity to fasting plasma glucose and A1C. *Diabetes Care*, 30: 1120-4, 2007.
- [14] Ediger MN, Maynard JD. Noninvasive optical detection of impaired glucose tolerance: a comparison against FPG and A1C. *Review of Endocrinology*, 1: 62-64, 2007.
- [15] Hull EL, Ediger MN, Unione AHT, Deemer EK, Stroman ML, Baynes JW. Noninvasive, optical detection of diabetes: model studies with porcine skin. *Optics Express*, 12:4496-4510, 2004.
- [16] Edward L. Hull, PhD et al. Non-invasive skin fluorescence spectroscopy for detection of abnormal glucose tolerance. *Journal of Clinical & Translational Endocrinology*: 1 (2014) 92e99.